Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT

Abstract

Objective To assess the effect of aspirin use in low-risk pregnancy on: (1) pregnancy-associated plasma protein-A (PAPP-A) and placental-like growth factor (PLGF); (2) urinary albumin-to-creatinine ratio (ACR) and blood pressure; (3) fetal growth parameters; and (4) placental histopathology.

Study Design This secondary analysis from the T rial of low-dose aspirin with an E arly S creening T est for preeclampsia and growth restriction randomized controlled trial was based on low-risk nulliparous women randomized at 11 weeks to (1) aspirin 75 mg; (2) no aspirin; and (3) aspirin based on the preeclampsia Fetal Medicine Foundation screening test. At baseline, women underwent assessment of blood pressure, PAPP-A, PLGF, and ACR, repeated 9 to 10 weeks postaspirin, in addition to fetal growth assessment. Gross and histopathological placental analyses were performed in line with Amsterdam criteria.

Results A total of 445 subjects were included (aspirin n = 163 [36.6%]; no aspirin n = 282 [63.4%]). Although the fetal-to-placental weight ratio was significantly greater in the aspirin group (7.5 [±1.3] vs. 7.3 [±1.4], p = 0.045), as was change in ultrasound assessed estimated fetal weight from second to third trimesters (1,624.5 g [±235.1] vs. 1,606.2 [±189.4], p = 0.042), this was invalidated by the lack of a difference in birth weight. Aspirin did not significantly impact on change in serum or urine preeclampsia biomarkers, maternal blood pressure, or placental histopathology.

Conclusion Aspirin use in low-risk pregnancy does not appear to impact on preeclampsia biomarkers, fetal growth, or placental pathology.

Keywords

aspirin - pregnancy-associated protein A - placental-like growth factor - albumin-to-creatinine ratio - fetal growth - placental histopathology

Note

This study was conducted at the National Maternity Hospital, Holles Street, Dublin, Ireland.

• References

• 1 Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160 (10) 695-703
• 2 Higgins JR, Brennecke SP. Pre-eclampsia--still a disease of theories?. Curr Opin Obstet Gynecol 1998; 10 (02) 129-133
• 3 Navaratnam K, Alfirevic A, Alfirevic Z. Low dose aspirin and pregnancy: how important is aspirin resistance?. BJOG 2016; 123 (09) 1481-1487
• 4 Rolnik DL, Wright D, Poon LC. , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
• 5 Villa PM, Kajantie E, Räikkönen K. , et al; PREDO Study group. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 2013; 120 (01) 64-74
• 6 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; 2 (02) CD004659
• 7 Mone F, Mulcahy C, McParland P. , et al. An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): trial protocol. Contemp Clin Trials 2016; 49: 143-148
• 8 Mone F, Mulcahy C, McParland P. , et al. Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial. BMJ Open 2018; 8 (07) e022056
• 9 Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements--a prospective study. Am J Obstet Gynecol 1985; 151 (03) 333-337
• 10 Poon LCY, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation. Fetal Diagn Ther 2012; 31 (01) 42-48
• 11 Khong TY, Mooney EE, Ariel I. , et al. Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med 2016; 140 (07) 698-713
• 12 Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH. Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 46 (01) 42-50
• 13 Bujold E, Roberge S, Lacasse Y. , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1): 402-414
• 14 Stirnemann J, Villar J, Salomon LJ. , et al; International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st); Scientific Advisory Committee; Steering Committees; INTERGROWTH-21st; INTERBIO-21st; Executive Committee; In addition for INTERBIO 21st; Project Coordinating Unit; Data Analysis Group; Data Management Group; In addition for INTERBIO 21st; Ultrasound Group; In addition for INTERBIO-21st; Anthropometry Group; In addition for INTERBIO-21st; Laboratory Processing Group; Neonatal Group; Environmental Health Group; Neurodevelopment Group; Participating countries and local investigators; In addition for INTERBIO-21st; In addition for INTERBIO-21st. International estimated fetal weight standards of the INTERGROWTH-21st Project. Ultrasound Obstet Gynecol 2017; 49 (04) 478-486
• 15 Kehl S, Schmidt U, Spaich S, Schild RL, Sütterlin M, Siemer J. What are the limits of accuracy in fetal weight estimation with conventional biometry in two-dimensional ultrasound? A novel postpartum study. Ultrasound Obstet Gynecol 2012; 39 (05) 543-548
• 16 Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “great obstetrical syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 2011; 204 (03) 193-201
• 17 Ogge G, Chaiworapongsa T, Romero R. , et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 2011; 39 (06) 641-652
• 18 Mifsud W, Sebire NJ. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther 2014; 36 (02) 117-128
• 19 Luque-Fernandez MA, Ananth CV, Jaddoe VW. , et al. Is the fetoplacental ratio a differential marker of fetal growth restriction in small for gestational age infants?. Eur J Epidemiol 2015; 30 (04) 331-341
• 20 Christians JK, Grynspan D, Greenwood SL, Dilworth MR. The problem with using the birthweight:placental weight ratio as a measure of placental efficiency. Placenta 2018; 68: 52-58
• 21 O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol 214 2016; 103.e1-103.e12
• 22 Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 110-120